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Abstract  
Bisphosphonates (BPs) are an important class of drugs used in the treatment of abnormal calcium 
metabolism diseases. The first syntheses of bisphosphonates derived from indazole, substituted 
at the N-1, N-2 and C-3 positions are reported. The 1-hydroxy-1,1-bisphosphonates were 
synthesized from the corresponding carboxylic acid or acyl chloride compounds, by two 
different methods. These BPs have a side chain with different lengths ((CH2)n, n = 0-5) between 
the indazole ring and the bisphosphonate group.  
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Introduction 
 
Bisphosphonates (BPs) are an important class of drugs known by their broad spectrum of 
therapeutic applications in the treatment of diseases characterized by abnormal calcium 
metabolism, such as hypercalcemia, osteoporosis and tumor-associated osteolysis.1 BPs were 
first developed as pharmaceuticals in the mid-1960´s and have been used as an effective 
treatment for Paget’s disease.2 Since then, many BPs were synthesized and made commercially 
available due to their value in the treatment of disorders of bone mineral.3 These compounds 
have high affinity for calcium and therefore to target the bone mineral, where they appear to be 
internalized selectively by bone-reabsorbing osteoclasts and induce their apoptosis.4 BPs offer 
several advantages in treating osteoporosis since they are bone-tissue specific, have minimal side 
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effects, have no known risk of carcinogenesis and have antiresorptive efficacy equivalent to, or 
even greater than estrogens.5 
 In addition, functional BPs showed anti-tumour properties which includes activity against 
bone metastases secondary to breast cancer6 and prostate cancer,7 inhibition of cell proliferation, 
invasion and adhesion to bone.8 They also showed to have applications in the inhibition of 
angiogenesis9 and as anti-inflammatory agents.10 BPs are also useful as novel ligands in well-
defined radioactive metal complexes that can be used in magnetic resonance imaging and 
imagiology, scintigraphy and radiotherapy applications.11 Another property of these compounds 
under investigation is their chelating efficiency toward metal ions; several laboratories are 
developing BPs as chelating agents for the treatment of human metal intoxications.12 
 Chemically, BPs are structural analogues of pyrophosphonates in which the oxygen atom of 
P-O-P is replaced by a carbon atom, resulting in P-C-P bonds which are stable toward heat and 
chemical reagents, completely resistant to enzymatic degradation, and usually have low 
toxicity.1,13 
 The biological activities of these compounds are determined by the nature of the alkyl moiety 
bound to the bisphosphonic structure as well as the functional groups located on the alkyl chain, 
with the nitrogen-containing homologues, such as risedronate and zoledronate, being amongst 
the most potent BPs in the treatment of several bone diseases. The most potent BPs contains 1 or 
2 nitrogen atoms in a heteroaromatic moiety linked via a small side chain to a geminal 
bisphosphonate group. Some of the heterocyclic-BPs are drugs commercially available, such as 
Actonel® (risedronate sodium) and Zometa® (zoledronic acid).14,15 The BPs usually present a 
very low oral bioavailability due to the high hydrophilicity of their phosphonate groups.16 
 Indazole derivatives are pharmacologically important compounds and the indazole ring 
system forms the basis of several drug molecules.17 However, the chemistry of indazole remains 
less studied in comparison with other heteroaromatic compounds, such as indole or 
benzimidazole. 
 The indazole ring has two nitrogen atoms, like the 3rd generation BPs, which can lead to an 
increased effect of BPs and can be functionalized with high selectivity at different positions. The 
length of the side chain and the different positions at the indazole ring, where it could be bonded, 
can afford a large number of indazolebisphosphonates, presenting a promising field to achieve 
new BPs with biological and therapeutical properties. 
 To the best of our knowledge, no BPs derived from indazole were synthesized. The aim of 
this work is to obtain new BPs derived from indazole with high potential biological/therapeutical 
activities. 
 Here, we report the synthesis and structural characterization of new indazole BPs substituted 
at different C- or N- positions of indazole rings, and with a side chain with different lengths 
(CH2)n n=0-5 from the bisphosphonate function to the nitrogen or carbon atom of the ring.  
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Results and Discussion 
 
Synthesis 
The new 1-hydroxy-1,1-indazolebisphosphonates were prepared from the corresponding 
carboxylic acid derived from indazole, substituted at N-1, N-2 and C-3 positions, with a side 
chain with different length 1a-e, 4a-e, 6 and 8. The synthesis of carboxylic acids 1a-e and 4a-e, 
and their characterization were reported previously.18  
 Several methods for the synthesis of 1-hydroxy-1,1-bisphosphonates have been reported.19 
The most used method involves the reaction of a carboxylic acid with phosphorus trichloride and 
phosphorous acid or phosphoric acid, followed by acidic hydrolysis (Method A).15,20 Recently, a 
modified Arbuzov reaction method was proposed by Lecouvey et al.21 This method involves the 
reaction of an acyl chloride with tris(trimethylsilyl)phosphite, followed by methanolysis (Method 
B).21 
 1-Hydroxy-1,1-indazolebisphosphonate derivatives 2a-e were prepared in moderate yield 
from the corresponding carboxylic acid derived from an indazole substituted at the N-1 position 
1a-e (n=1-5), by treatment with a mixture of phosphoric acid and phosphorus trichloride, 
followed by acid hydrolysis (Table 1). The separation and purification of BPs were done by 
precipitation in acetone and methanol, being always a difficult and tedious process, as previously 
described by other authors.15 
 
Table 1. Preparation of bisphosphonates 2a-e derived from indazole substituted at N-1 position 
i) H3PO4 (85%)/PCl3
N
N
(CH2)nCO2H
1a-e 2a-e
N
N
ii) HCl (9 N)
PO3H2
OH
PO3H2
(  )
n
 
 
Compound n Yield (%) 
2a 1 16 
2b 2 60 
2c 3 44 
2d 4 62 
2e 5 50 
 
 In the case of the compound 2a, with a single methylene group, the yield of the reaction was 
very low. So, the Lecouvey’s alternative method (Method B) was used. The acyl chloride 3a was 
prepared in situ, by reaction of the carboxylic acid 1a with thionyl chloride, which showed to be 
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very unstable. The acyl chloride 3a reacted with tris(trimethylsilyl)phosphite, followed by 
methanolysis, to afford BP 2a, in 71% yield (Scheme 1).  
 
i) SOCl2, CHCl3
N
N
CH2CO2H
N
N
OH
PO3H2
PO3H2
ii) [(CH3)3SiO]3P, THF
N
N
CH2COCl
in situ
2a   71%1a 3a
iii) MeOH
 
 
Scheme 1 
 
 The 1-hydroxy-1,1-indazole-bisphosphonate derivatives 5a-e were also prepared by reaction 
of the corresponding carboxylic acid derived from indazole substituted at N-2 position 4a-e (n = 
1-5) with phosphorus trichloride and phosphoric acid, followed by acidic hydrolysis (Method A). 
However, the reactions afforded the BPs in low yields (exception for BP 5e, with n=5) (Table 2).  
In order to increase the yields of these syntheses, the Lecouvey’s method (Method B) was used 
and the synthesis of compound 5b afforded these BP in 77% yield, but compounds 5a and 5c 
were always isolated in low yields. The lower solubility of compounds 4a and 4c, in the solvent 
used to prepare the corresponding acyl chloride and the lower stability of the acyl chloride 
should explain the low yield of BP 5a and BP 5c (Table 2). 
 
Table 2. Preparation of bisphosphonates 5a-e derived from indazole substituted at N-2 position  
N
N
N
N
OH
PO3H2
PO3H2(  )
n
(CH2)nCO2H
4a-e 5a-e
Method A or Method B
 
 
Method A: (i) H3PO4 (85%)/PCl3; (ii) HCl (9 N). Method B: (i) SOCl2 (4 eq.); (ii) [(CH3)3SiO]3P 
(2 eq.); (iii) MeOH 
Compound n Method Yield (%) 
A 6 
5a 1 
B - 
A - 
5b 2 B 77 
A 17 
5c 3 
B 17 
5d 4 A 39 
5e 5 A 87 
General Papers ARKIVOC 2009 (xi) 69-84 
ISSN 1551-7012 Page 73 ©ARKAT USA, Inc. 
 1-Hydroxy-1,1-indazolebisphosphonate 7, prepared from the carboxylic acid 6, substituted at 
the indazole C-3 position, was synthesized following the method of Lecouvey (Method B).21 The 
reaction of commercially available 1H-indazole-3-carboxylic acid 6 with SOCl2, to produce in 
situ the corresponding acyl chloride, followed by reaction with tris(trimethylsilyl)phosphite and 
hydrolysis, afforded the BP 7, as white powder, in 67% yield (Scheme 2). 
 
i) SOCl2 (4 eq.)
N
N
H
6
N
N
7  67%
HO
PO3H2
PO3H2
COOH
H
ii)  [(CH3)3SiO]3P (2 eq.)
iii) MeOH
 
 
Scheme 2 
 
 To increase the length of the alkyl side chain at the C-3 position, the carboxylic acid 
derivative 8 was synthesized according to literature procedures, from o-nitrobenzaldehyde, 
malonic acid and ammonium acetate in acetic acid.22 BP 9 was obtained by Lecouvey’s method 
(Method B) from the corresponding carboxylic acid with 16% yield (Scheme 3). 
 
N
N
H
8
N
N
9  16%
HO
PO3H2
PO3H2
CH2COOH
H
i) SOCl2 (4 eq.)
ii)  [(CH3)3SiO]3P (2 eq.)
iii) MeOH
 
 
Scheme 3 
 
Spectroscopic characterization 
Compounds 2a-e, 5a-e, 7 and 9 were fully characterized by NMR (including bidimensional 
techniques), IR spectroscopy, mass spectrometry (low and high resolution) and elemental 
analysis. 
 The BPs were submitted to Electron Impact Ionization (EI) Mass Spectrometry, but most did 
not show the molecular ion. Fast Atom Bombardment (FAB) or Electrospray Ionization (ESI) 
methods were used to show the molecular ion of all BPs, which confirmed their proposed 
molecular formulae. The mass spectra showed characteristic fragment ions corresponding to the 
loss of H2O and H3PO3 fragments.23 
 The IR spectra of indazolebisphophonates showed the disappearance of the strong C=O 
stretching band from the carboxylic acid (starting material) and the appearance of two strong 
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characteristic bands at approximately 1250-1100 and 1100-900 cm-1, due to the ν(P=O) (1200-
1160 cm-1), ν(P-OH) (≈ 1000 and ≈ 925 cm-1) and δ(POH) (around 1080 cm-1) bands of 
bisphosphonate group.24 A broad band with a maximum near 3400 cm-1 is attributed to the O-H 
stretching band, in agreement with the presence of the bisphosphonate group. C-H(Ar) and CH2 
stretching bands are observed over this ν(O-H) band. The ν(O-H) band also overlaps with the 
very large and weak ν(PO-H) and δ(POH) bands, with maximum around 2600-2800 cm-1.24 
 The bisphosphonate structure of BPs was readily identified by analysis of NMR data. The 
unambiguous identification of isomers of indazolebisphosphonates derivatives substituted at N-1, 
N-2, and C-3, was carried out by 1H and 13C NMR spectroscopy, including DEPT and APT, and 
two-dimensional NMR techniques (HETCOR, COSY, HSQC and HMBC). 
 The 1H NMR and 13C NMR spectra of N-1 and N-2 isomers of indazolebisphosphonates 2a-e 
and 5a-e are sufficiently different to be used as diagnostic tools for the position of substitution. 
The main resonances in the 1H NMR spectra of BPs 2a-e are: (i) the resonance of CH2 protons, 
which appears at δ 1.23-2.35 ppm, (ii) the resonance of NCH2 protons, which appears at δ 4.36-
4.85 ppm, (iii) four resonances in the region of δ 7.11-7.75 ppm, relative to the aromatic ring 
protons, usually as two one proton doublets (4-H and 7-H) and two one proton triplets (5-H and 
6-H), (iv) a singlet (or a doublet, with a very small coupling constant, J 0.6 Hz) at δ 7.99-8.12, 
which corresponds to the 3-H proton. 
 The 1H NMR spectra of BPs 5a-e also showed four resonances in the region δ 7.01-7.68 
ppm, attributed to the aromatic ring protons, usually as two one proton doublets (4-H and 7-H) 
and two one proton triplets (5-H and 6-H); these resonances are generally 0.10 ppm upfield from 
the corresponding signals of the BPs 2a-e. The 3-H proton is observed as one proton singlet or 
doublet (J 0.6 Hz) at δ 8.30-8.42 ppm, which are generally 0.30 ppm downfield from the signals 
of the BPs 2a-e. Both BPs 2a and 5a (all with n=1) present the 3-H proton resonance 0.12 ppm 
downfield relatively to the BPs 2b-e and 5b-e (with aliphatic side chains with more than one 
methylene group). Compounds 2a and 5a showed a triplet (3JH,P ≈10 Hz), at 4.85 and 4.90 ppm, 
respectively, due to the coupling of NCH2 protons with two phosphorous atoms, supporting the 
proposed structures of two equivalent phosphonate groups attached to the same carbon.  
 The indazoleBPs 7 and 9, derived from indazole substituted at C-3, showed four resonances 
in the region of δ 7.01-7.28 ppm relative to the aromatic ring protons, as two one proton doublets 
(4-H and 7-H) and two one proton triplets (5-H and 6-H). The BP 7, which has the 1-hydroxy-
1,1-bisphosphonate group bonded to the pyrazole ring of the indazole, with no aliphatic side 
chain, present the doublet, relative to H-4, 0.5 ppm downfield relative to indazoleBP 9 (with a 
methylene group at the side chain). The 1H NMR spectrum of BP 9 has a CH2 triplet (3JH,P 14 
Hz) at δ 3.57 ppm, which confirmed the presence of two equivalent phosphonate groups attached 
to the same carbon. 
 13C NMR spectroscopy also confirms the presence of the bisphosphonate group. The 
appearance of a quaternary carbon triplet (disappearing in DEPT-135 13C NMR spectra) at δ 
71.1-74.3 ppm (with 2JC,P 143-146 Hz) supported the proposed structures with two phosphonate 
groups attached to the same carbon (P-COH-P) (Tables 3-5). 13C NMR is also the best 
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spectroscopic method for assigning the position of substitution, since the C-3, C-7 and C-7a 
showed different chemical shifts between the N-1, N-2 and C-3 isomers (Table 3-5). In N-1 
substituted indazoleBPs spectra, C-3 was generally shifted downfield 10 ppm, and C-7 and C-7a 
were shifted upfield, relatively to the corresponding carbons in N-2 substituted indazoleBPs. The 
C-3 substituted isomers (BPs 7 and 9) present C-7 and C-7a with similar chemical shifts to the 
N-1 isomers but the C-3 quaternary carbon atom was observed further downfield, at 
approximately 8 ppm. 
 
Table 3. 13C NMR data of compound N-1 isomers 2a-e 
BP n 13C NMR, δ 
  Ar:C-7 Ar:C-5 Ar:C-4 Ar:C-6 Ar:C-3 Ar:C-3a Ar:C-7a 
C(OH)- 
(PO3H2)2 
NCH2 CH2 
2aa 1 110.8 120.4 120.6 126.1 133.1 123.0 140.4 
73.2  
(t, JCP 
143) 
50.0  
2ba 2 109.5 120.4 121.0 126.0 132.6 123.6 138.8 
71.2  
(t, JCP 
143) 
44.3 33.6 
2ca 3 109.8 120.3 120.9 125.9 132.3 123.5 139.1 
72.2  
(t, JCP 
143) 
49.0 24.3, 30.6 
2db 4 110.5 121.9* 122.2* 127.9 133.7 125.1 140.7 
74.2  
(t, JCP 
146) 
49.5 
22.2, 31.7, 
34.6 
2eb 5 110.5 121.9* 122.2* 128.0 133.7 124.9 140.9 
74.3  
(t, JCP 
146) 
49.4 
24.1, 28.4, 
30.7, 35.0 
a Solvent for NMR: DMSO-d6. b Solvent for NMR: MeOD-d4. * These assignments may be 
reversed. 
 
 The assignment of the C-3 isomers was supported by HSQC and HMBC spectra (Table 5). 
The connectivities found in these spectra allowed the full assignment of proton and carbon 
atoms, including the three quaternary carbon resonances. We may note that C-3 and C-7a have 
similar chemical shifts, but C-3, relative to C-7a, is observed upfield in BP 7 and downfield in 
BP 9. 
 The proton-decoupled 31P NMR spectra of indazoleBPs 2, 5, 7 and 9 showed a single signal 
in the range of 15.4-21.1 ppm, which confirmed that two phosphorus atoms are magnetically 
equivalent. The chemical shifts of phosphorus atoms are similar between the corresponding 
isomers. The lower chemical shift is observed for indazoleBP 7, with no aliphatic side chain, 
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with the phosphorus atoms connected to a carbon atom directly bonded to the aromatic indazole 
ring. The chemical shift generally increases with the increasing number of methylene groups in 
side chain.  
 
Table 4. 13C NMR data of compound N-2 isomers 5a-e in DMSO-d6 
13C NMR, δ 
BP n 
Ar:C-7 Ar:C-5 Ar:C-4 Ar:C-6 Ar:C-3 Ar:C-3a Ar:C-7a
C(OH)- 
(PO3H2)2 
NCH2 CH2 
5a 1 116.6 121.3* 121.5* 127.6 126.8 121.2 147.8 
73.0 
(t, JCP 141) 
55.0  
5b 2 116.8 120.9 120.6 125.4 123.5 121.4 147.9 
71.1 
(t, JCP 143) 
48.8 34.6 
5c 3 117.1 121.6 120.9 125.7 123.9 121.2 148.1 
72.3 
(t, JCP 142) 
53.7 25.2, 30.5 
5d 4 117.0 121.4 120.7 125.4 123.8 121.0 148.0 
72.4 
(t, JCP 143) 
52.9 
20.5, 31.1, 
33.0 
5e 5 116.9 121.0 120.7 125.5 124.0 121.4 147.9 
72.5 
(t, JCP 143) 
52.8 
22.6, 26.9, 
30.1, 33.3 
* These assignments may be reversed. 
 
Table 5. 13C NMR data of compounds 7 and 9 in DMSO-d6 
13C NMR, δ 
BP 
Ar:C-7 Ar:C-5 Ar:C-4 Ar:C-6 Ar:C-3 Ar:C-3a Ar:C-7a C(OH)(PO3H2)2 CH2 
7 109.6 119.2 125.2 125.9 140.9 120.3 142.1 74.6 (t, JCP 151)  
9 110.2 120.0 121.1 126.7 141.7 122.6 140.3 72.1 (t, JCP 143) 19.2 
 
 
Conclusions 
 
We report the first synthesis of 1-hydroxy-1,1-indazolebisphosphonates substituted at N-1, N-2 
and C-3 positions of indazole ring, with the side chain with different (CH2)n groups (n=1-5 for 
N-1 and N-2 isomers and n=0,1 for C-3 BPs), in moderated to good yields, starting from their 
corresponding carboxylic acids or acyl chlorides. In order to increase the synthetic yields, two 
different methods were used.  
 Despite the difficulty in the separation and purification of these bisphosphonates, they were 
fully characterized using the usual spectroscopic methods, especially NMR spectroscopy, 
including two dimensional NMR techniques. NMR spectroscopic characterization allowed the 
assignment of 1H- and 13C- atoms of different BPs. The presence of a quaternary carbon triplet 
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confirmed the presence of the bisphosphonate group with two equivalent phosphorous atoms 
bonded to the same carbon atom.  
 This work also showed that NMR spectroscopy allowed the easy identification of the N-1, N-
2 and C-3 isomers since they showed spectra with different chemical shifts, especially the C-3, 
C-7 and C-7a 13C NMR signals. The N-1 indazole BPs showed C-3 carbon atom generally 
shifted downfield (≈10 ppm) relative to the corresponding carbon atom in N-2 indazole BPs, 
while C-7 and C-7a were shifted upfield. The C-7 and C-7a carbon atoms of C-3 substituted BPs 
(BPs 7 and 9) have similar chemical shifts relative to N-1 isomers but the C-3 quaternary carbon 
atom was observed further downfield, at approximately 8 ppm. Connectivities in HMBC spectra 
of BPs 7 and 9 also showed that those compounds present inversion in the chemical shift of C-3 
and C-7a quaternary carbon atoms. 
 These synthesized BPs will be submitted to in vitro and in vivo studies to assess their 
potential therapeutic applications (studies currently in progress).  
 
 
Experimental  Section 
 
General Procedures. NMR spectra were recorded on Bruker AMX 300 and on a Bruker Avance 
II 300 (1H 300 MHz, 13C- 75 MHz, 31P 121 MHz) and on a Bruker Avance II 400 (1H 400 MHz, 
13C- 100 MHz, 31P 162 MHz) spectrometers. Chemical shifts (δ) are reported in ppm and 
coupling constants (J) in Hz. 1H- and 13C NMR chemical shifts were assigned using DEPT and 
APT sequences, and bidimensional COSY, HETCOR, HSQC and HMBC techniques. 
Assignments were made by comparison of chemical shifts, peak multiplicities and J values, and 
were supported by bidimensional heteronuclear HMBC and HSQC correlation techniques. 
Infrared spectra were recorded on a Perkin Elmer FT-IR 1725xIR Fourier Transform 
spectrophotometer using KBr discs. The bands are quoted in cm-1. Low resolution and high 
resolution (HRMS) mass spectra analyses were performed at the ‘C.A.C.T.I. - Unidad de 
Espectrometria de Masas’ at the University of Vigo, Spain, on a VG AutoSpect M, MicroTOF 
(Bruker Daltonics) or APEX-Q (Bruker Daltonics) instrument. Elemental analysis were 
performed on a CE instrument EA 1110CHNS O and a Fisons EA-1108 elemental analyzer. 
Melting points were determined on a Reichert Thermovar melting point apparatus and are 
uncorrected. 
All the reactions involving air sensitive reagents were performed under an atmosphere of dry 
nitrogen and all solvents were degassed before use. All solvents were distilled under a nitrogen 
atmosphere. THF were distilled from sodium benzophenone ketyl. CHCl3 was distilled from 
calcium hydride. 
1H-Indazole-3-carboxylic acid 6 is commercially available (Aldrich). Carboxylic acids 1a-e and 
3a-e derived from indazole substituted at N-1 or N-2 position, with side chains with different 
lengths (n=1-5), were prepared as already reported in the literature.18 Carboxylic acids 8 derived 
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from indazole substituted at C-3 were synthesized in a two step synthesis according to reported 
synthetic procedures.22 
 
General procedure 1 (Method A) 
A mixture of a carboxylic acid (1 eq.), H3PO4 (85%) (2 eq.) and chlorobenzene was heated to 
100-110 °C with stirring. After all solids were dissolved, PCl3 (3 eq.) was added slowly and the 
reaction mixture was vigorously stirred at 100-110 °C for 5 h. After cooling, chlorobenzene was 
decanted and 9 N HCl was added to the residue. The resulting solution was refluxed for 3 h and 
the solvent was removed under reduced pressure. Acetone and methanol were added to 
precipitate the 1-hydroxy-1,1-indazolebisphosphonate as a white powder, which was washed 
with acetone and dried.  
 
General procedure 2 (Method B) 
A mixture of a carboxylic acid (1 eq.) in CHCl3 and thionyl chloride (4 eq.) was kept under 
reflux for 2 h. Solvents were removed under reduced pressure to give the corresponding acyl 
chloride, which was immediately used without further purification. The crude acyl chloride was 
dissolved in dry THF and tris(trimethylsilyl)phosphite (2 eq.) was added. Then, the mixture was 
stirred at room temperature for 30 min. The excess solvent was removed under reduced pressure 
and methanol was added and the mixture was stirred for 1 h. After solvent removal under 
reduced pressure, the residue was washed with ethyl ether and precipitated with acetone. 
 [1-Hydroxy-2-(1H-indazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) (2a). Following general 
procedure 1 (Method A), BP 2a was isolated as a white powder (16%), mp 200-201 ºC. υmax 
(KBr) (cm-1): 3567, 3428, 3152, 3120, 3014, 2972, 2794, 1629, 1519, 1464, 1433, 1412, 1383, 
1322, 1191, 1158, 1136, 1106, 1076, 1007, 963, 900, 863, 766, 758, 659, 608, 563, 540, 455.  
1H NMR (300 MHz, DMSO-d6): δ (ppm) = 4.85 (2H, t, JH,P 10.2, NCH2C(OH)(PO3H2)2), 7.12 
(1H, t, J 7.2, ArH, 5-H), 7.37 (1H, dt, J 7.2 and 0.9, ArH, 6-H), 7.61 (1H, d, J 8.1, ArH, 7-H), 
7.74 (1H, d, J 8.1, ArH, 4-H), 8.12 (1H, d, J 0.6, 3-H). 13C NMR (75 MHz, DMSO-d6): δ 50.0 
(NCH2), 73.2 (t, JCP 143, C(OH)(PO3H2)2), 110.8 (Ar:C-7), 120.4 (Ar:C-5), 120.6 (Ar:C-4), 
126.1 (Ar:C-6), 133.1 (Ar:C-3), 123.0 (Ar:C-3a), 140.4 (Ar:C-7a). 31P NMR (121 MHz, H3PO4/ 
DMSO-d6): δ (ppm) = 17.1. MS (FAB) m/z: 323 ([M+H]+), 305 ([M+H]+- H2O), 241 ([M+H]+- 
H3PO3). HRMS (FAB) Calcd for C9H13N2O7P2 323.0198 : [M+H]+, found 323.0205. Found: C, 
31.93, H, 4.16, N, 8.19. C9H12N2O7P2. H2O requires: C, 31.78, H, 4.15, N, 8.24%. 
[1-Hydroxy-3-(1H-indazol-1-yl)propane-1,1-diyl]bis(phosphonic acid) (2b). Following 
general procedure 1 (Method A), BP 2b was isolated as a white powder (60%), mp 127-130 ºC. 
υmax (KBr) (cm-1): 3534, 3494, 3417, 3129, 3044, 2953, 2922, 2782, 1645, 1616, 1504, 1465, 
1431, 1380, 1368, 1323, 1278, 1246, 1231, 1194, 1172, 1151, 1073, 1018, 941, 920, 899, 875, 
849, 765, 754, 665, 635, 608, 567, 546, 534, 479, 456. 1H NMR (300 MHz, DMSO-d6): δ 2.35 
(2H, m, NCH2CH2), 4.67 (2H, m, NCH2CH2), 7.13 (1H, t, J 7.2, ArH, 5-H), 7.39 (1H, t, J 7.5, 
ArH, 6-H), 7.61 (1H, d, J 8.4, ArH, 7-H), 7.75 (1H, d, J 8.1, ArH, 4-H), 8.04 (1H, s, 3-H).  
13C NMR (75 MHz, DMSO-d6): δ 33.6 (NCH2CH2), 44.3 (NCH2CH2), 71.2 (t, JCP 143, 
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C(OH)(PO3H2)2), 109.5 (Ar:C-7), 120.4 (Ar:C-5), 121.0 (Ar:C-4), 126.0 (Ar:C-6), 132.6 (Ar:C-
3), 123.6 (Ar:C-3a), 138.8 (Ar:C-7a). 31P NMR (121 MHz, H3PO4/ DMSO-d6): δ 19.8. MS 
(FAB) m/z: 337 ([M+H]+), 255 ([M+H]+- H3PO3). HRMS (FAB) Calcd for C10H15N2O7P2 
337.0355 [M+H]+. Found: m/z 337.0367. Found: C, 33.83, H, 4.58, N, 7.91. C10H14N2O7P2. H2O 
requires: C, 33.91, H, 4.55, N, 7.91%. 
 [1-Hydroxy-4-(1H-indazol-1-yl)butane-1,1-diyl]bis(phosphonic acid) (2c). Following general 
procedure 1 (Method A), BP 2c was isolated as a white powder (44%), mp 103-104 ºC. υmax 
(KBr) (cm-1): 3400, 3121, 2946, 1636, 1459, 1414, 1390, 1333, 1192, 1144, 1114, 1078, 1001, 
951, 861, 846, 765, 670, 656, 590, 563, 540, 516, 485, 435. 1H NMR (300 MHz, DMSO-d6): δ 
1.95 (2H, m, CH2C(OH)), 2.10 (2H, m, NCH2CH2), 4.36 (2H, t, J 6,9, NCH2CH2), 7.11 (1H, t, J 
7.2, ArH, 5-H), 7.36 (1H, dt, J 7.5 and 0.9, ArH, 6-H), 7.63 (1H, d, J 8.4, ArH, 7-H), 7.73 (1H, 
d, J 7.8, ArH, 4-H), 8.02 (1H, d, J 0.6, 3-H). 13C NMR (75 MHz, DMSO-d6): δ 24.3 (NCH2CH2), 
30.6 (CH2C(OH)), 49.0 (NCH2CH2), 72.2 (t, JCP 143, C(OH)(PO3H2)2), 109.8 (Ar:C-7), 120.3 
(Ar:C-5), 120.9 (Ar:C-4), 125.9 (Ar:C-6), 132.3 (Ar:C-3), 123.5 (Ar:C-3a), 139.1 (Ar:C-7a).  
31P NMR (121 MHz, H3PO4/ DMSO-d6): δ (ppm) = 20.6. MS (FAB) m/z: 351 ([M+H]+), 333 
([M+H]+- H2O), 269 ([M+H]+- H3PO3). HRMS (FAB) Calcd for C11H17N2O7P2 351.0511. 
[M+H]+. Found: m/z 351.0514. 
 [1-Hydroxy-5-(1H-indazol-1-yl)pentane-1,1-diyl]bis(phosphonic acid) (2d). Following 
general procedure 1 (Method A), the BP 2d was isolated as a white powder (62%), mp 128-130 
ºC. υmax (KBr): 3291, 3138, 2967, 2924, 2855, 2759, 1634, 1522, 1466, 1385, 1323, 1262, 1190, 
1162, 1142, 1084, 1053, 1004, 965, 891, 759, 669, 530, 469, 430cm-1. 1H NMR (300 MHz, 
MeOD-d4): δ 1.77 (2H, m, CH2), 1.89 (2H, m, CH2), 2.12 (2H, m, CH2), 4.42 (2H, t, J 7.2, 
NCH2CH2), 7.13 (1H, m, ArH, 5-H), 7.40 (1H, m, ArH, 6-H), 7.55 (1H, dd, J 8.7 and 0.9, ArH, 
7-H), 7.73 (1H, d, J 8.1, ArH, 4-H), 7.99 (1H, d, J 0.6, 3-H). 13C NMR (75 MHz, MeOD-d4): δ 
22.2, 31.7, 34.6 (CH2), 49.5 (NCH2CH2), 74.2 (t, JCP 146, C(OH)(PO3H2)2), 110.5 (Ar:C-7), 
121.9, 122.2 (Ar:C-4,C-5), 127.9 (Ar:C-6), 133.7 (Ar:C-3), 125.1 (Ar:C-3a), 140.7 (Ar:C-7a). 
31P NMR (121 MHz, H3PO4/ MeOD-d4): δ 19.5. MS (FAB) m/z: 365 ([M+H]+), 347 ([M+H]+- 
H2O), 283 ([M+H]+- H3PO3). HRMS (FAB) m/z Calcd for C12H19N2O7P2 365.0668 [M+H]+, 
found 365.0674. 
[1-Hydroxy-6-(1H-indazol-1-yl)hexane-1,1-diyl]bis(phosphonic acid) (2e). Following general 
procedure 1 (Method A), BP 2e was isolated as a white powder (50%). mp 118-120 ºC. υmax 
(KBr) 3377, 3128, 2942, 2866, 1631, 1466, 1384, 1367, 1171, 1139, 1092, 1007, 947, 838, 754, 
670, 662, 514 cm-1. 1H NMR (300 MHz, MeOD-d4): δ (ppm) = 1.28 (2H, m, CH2), 1.73 (2H, m, 
CH2), 1.90 (4H, m, CH2), 4.42 (2H, t, J 6.9, NCH2CH2), 7.14 (1H, t, J 7.8, ArH, 5-H), 7.41 (1H, 
m, ArH, 6-H), 7.57 (1H, d, J 8.4, ArH, 7-H), 7.74 (1H, d, J 8.4, ArH, 4-H), 8.01 (1H, s, 3-H).  
13C NMR (75 MHz, MeOD-d4): δ (ppm) = 24.1, 28.4, 30.7, 35.0 (CH2), 49.4 (NCH2CH2), 74.3 
(t, JCP 146, C(OH)(PO3H2)2), 110.5 (Ar:C-7), 121.9, 122.2 (Ar:C-4, C-5), 128.0 (Ar:C-6), 133.7 
(Ar:C-3), 124.9 (Ar:C-3a), 140.9 (Ar:C-7a). 31P NMR (121 MHz, H3PO4/ MeOD-d4): δ (ppm) = 
21.1. MS (FAB) m/z: 379 ([M+H]+), 297 ([M+H]+- H3PO3). HRMS (FAB) m/z Calcd for 
C13H21N2O7P2 379.0824 [M+H]+; found 379.0808. 
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 [1-Hydroxy-2-(2H-indazol-2-yl)ethane-1,1-diyl]bis(phosphonic acid) (5a). Using general 
procedure 1 (Method A), compound 5a was isolated as a white powder (6%), mp 181ºC 
(decomp.), υmax (KBr) 3445, 2922, 2856, 1645, 1456, 1199, 1140, 1078, 1011, 945, 853, 752cm-
1. 1H NMR (300 MHz, DMSO-d6): δ  4.90 (2H, t, JHP 10.5, NCH2C(OH)(PO3H2)2), 7.04 (1H, t, J 
8.1, ArH), 7.27 (1H, t, J 8.4, ArH), 7.58 (1H, d, J 8.7, ArH), 7.72 (1H, d, J 8.4, ArH), 8.42 (1H, 
s, 3-H). 13C NMR (75 MHz, DMSO-d6): δ 55.0 (NCH2), 73.0 (t, JCP 141, C(OH)(PO3H2)2), 116.6 
(Ar:C-7), 121.3, 121.5 (Ar:C-4, C-5), 127.6 (Ar:C-6), 126.8 (Ar:C-3), 121.2 (Ar:C-3a), 147.8 
(Ar:C-7a). 31P NMR (121 MHz, H3PO4/ DMSO-d6): δ 16.5. MS (FAB) m/z: 323 ([M+H]+), 241 
([M+H]+- H3PO3). HRMS (FAB) m/z Calcd for C9H13N2O7P2 323.0198 [M+H]+. Found: 
323.0193. 
[1-Hydroxy-3-(2H-indazol-2-yl)propane-1,1-diyl]bis(phosphonic acid) (5b). Following 
general procedure 2 (Method B), compound 5b was isolated as a white powder (77%). mp 198-
200 ºC. υmax (KBr): 3432, 3294, 3109, 2894, 2618, 2553, 1639, 1528, 1432, 1390, 1370, 1246, 
1217, 1168, 1149, 1133, 1054, 1013, 989, 945, 926, 879, 772, 762, 719, 652, 611, 536, 470 cm-1. 
1H NMR (300 MHz, DMSO-d6): δ 2.49 (2H, m, NCH2CH2), 4.67 (2H, m, NCH2CH2), 7.02 (1H, 
t, J 8.1, ArH, 5-H), 7.22 (1H, t, J 8.4, ArH, 6-H), 7.58 (1H, d, J 8.7, ArH, 7-H), 7.68 (1H, d, J 
8.4, ArH, 4-H), 8.30 (1H, s, 3-H). 13C NMR (75 MHz, DMSO-d6): δ 34.6 (NCH2CH2), 48.8 
(NCH2CH2), 71.1 (t, JCP 143, C(OH)(PO3H2)2), 116.8 (Ar:C-7), 120.6 (Ar:C-4), 120.9 (Ar:C-5), 
123.5 (Ar:C-3), 125.4 (Ar:C-6), 121.4 (Ar:C-3a), 147.9 (Ar:C-7a). 31P NMR (121 MHz, H3PO4: 
DMSO-d6): δ 19.5. MS (FAB) m/z: 337 ([M+H]+), 255 ([M+H]+- H3PO3). HRMS (FAB) Calcd 
for C10H15N2O7P2 337.0355 [M+H]+, found 337.0370. Found: C, 32.41, H, 5.02, N, 7.40. 
C10H14N2O7P2. 2H2O requires C, 32.27, H, 4.87, N, 7.53%. 
[1-Hydroxy-4-(2H-indazol-2-yl)butane-1,1-diyl]bis(phosphonic acid) (5c). Following general 
procedure 1 (Method A) and the general procedure 2 (Method B), 5c was isolated as a white 
powder (17%), mp 174-175 ºC. υmax (KBr) (cm-1): 3421, 3220, 3132, 2958, 2928, 2781, 1637, 
1529, 1388, 1369, 1216, 1185, 1162, 1003, 990, 945, 760, 670, 648, 633, 613, 525, 510, 467.  
1H NMR (300 MHz, DMSO-d6): δ 1.90 (2H, m, CH2C(OH)), 2.20 (2H, m, NCH2CH2), 4.38 (2H, 
m, NCH2CH2), 7.01 (1H, t, J 7.5, ArH, 5-H), 7.21 (1H, t, J 8.7, ArH, 6-H), 7.57 (1H, d, J 8.7, 
ArH, 7-H), 7.68 (1H, d, J 8.4, ArH, 4-H), 8.30 (1H, s, 3-H). 13C NMR (75 MHz, DMSO-d6): δ 
25.2 (NCH2CH2), 30.5 (CH2C(OH)), 53.7 (NCH2), 72.3 (t, JCP 142, C(OH)(PO3H2)2), 117.1 
(Ar:C-7), 120.9 (Ar:C-4), 121.6 (Ar:C-5), 123.9 (Ar:C-3), 125.7 (Ar:C-6), 121.2 (Ar:C-3a), 
148.1 (Ar:C-7a). 31P NMR (121 MHz H3PO4/ DMSO-d6): δ 20.3. MS (FAB) m/z: 351 ([M+H]+), 
269 ([M+H]+- H3PO3). HRMS (FAB) Calcd for C11H17N2O7P2 351.0511. [M+H]+. Found: m/z 
351.0515. 
[1-Hydroxy-5-(2H-indazol-2-yl)pentane-1,1-diyl]bis(phosphonic acid) (5d). Following 
general procedure 1 (Method A), BP 5d was isolated as a white powder (39%). mp 202-203 ºC. 
υmax (KBr) (cm-1): 3398, 3199, 3016, 2958, 2853, 2685, 1638, 1528, 1388, 1364, 1241, 1172, 
1148, 1127, 1108, 1088, 1030, 996, 973, 930, 900, 828, 757, 744, 638, 610, 530, 520, 488, 478, 
468, 449. 1H NMR (300 MHz, DMSO-d6): δ 1.60 (2H, m, CH2), 1.84 (4H, m, CH2CH2), 4.35 
(2H, m, NCH2CH2), 7.01 (1H, t, J 7.5, ArH, 5-H), 7.21 (1H, t, J 8.4, ArH, 6-H), 7.57 (1H, d, J 
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8.7, ArH, 7-H), 7.67 (1H, d, J 8.4, ArH, 4-H), 8.33 (1H, s, 3-H). 13C NMR (75 MHz, DMSO-d6): 
δ 20.5, 31.1, 33.0 (CH2), 52.9 (NCH2CH2), 72.4 (t, JCP 143, C(OH)(PO3H2)2), 117.0 (Ar:C-7), 
120.7 (Ar:C-4), 121.4 (Ar:C-5), 123.8 (Ar:C-3), 125.4 (Ar:C-6), 121.0 (Ar:C-3a), 148.0 (Ar:C-
7a). 31P NMR (121 MHz, H3PO4/ DMSO-d6): δ 21.0. MS (FAB) m/z: 365 ([M+H]+). HRMS 
(FAB) m/z Calcd for C12H19N2O7P2 365.0668 [M+H]+. Found: m/z 365.0672. 
[1-Hydroxy-6-(2H-indazol-2-yl)hexane-1,1-diyl]bis(phosphonic acid) (5e). Following general 
procedure 1 (Method A), BP 5e was isolated as a white powder (87%), mp 144-145 ºC. υmax 
(KBr) (cm-1): 3367, 3126, 3108, 2929, 2861, 2764, 2695, 1637, 1528, 1466, 1458, 1388, 1367, 
1165, 1146, 1062, 1002, 939, 757, 668, 662, 612, 569, 519. 1H NMR (300 MHz, DMSO-d6): δ 
1.15 (2H, m, CH2), 1.59 (2H, m, CH2), 1.86 (4H, m, CH2), 4.39 (2H, m, NCH2CH2), 7.01 (1H, t, 
J 7.5, ArH, 5-H), 7.21 (1H, t, J 8.1, ArH, 6-H), 7.58 (1H, d, J 8.4, ArH, 7-H), 7.67 (1H, d, J 8.4, 
ArH, 4-H), 8.34 (1H, s, 3-H). 13C NMR (75 MHz, DMSO-d6): δ 22.6, 26.9, 30.1, 33.3 (CH2), 
52.8 (NCH2CH2), 72.5 (t, JCP 143, C(OH)(PO3H2)2), 116.9 (Ar:C-7), 120.7 (Ar:C-4), 121.0 
(Ar:C-5), 124.0 (Ar:C-3), 125.5 (Ar:C-6), 121.4 (Ar:C-3a), 147.9 (Ar:C-7a). 31P NMR (121 
MHz, H3PO4/ DMSO-d6): δ 21.1. MS (FAB) m/z: 379 ([M+H]+), 297 ([M+H]+- H3PO3). HRMS 
(FAB) Calcd for C13H21N2O7P2, 379.0824 [M+H]+. Found: m/z 379.0829. Found: C, 38.68, H, 
5.70, N, 6.80. C13H20N2O7P2. 4/3H2O requires: C, 38.81, H, 5.68, N, 6.96%. 
[Hydroxy(1H-indazol-3-yl)methanediyl]bis(phosphonic acid) (7). Following general 
procedure 2 (Method B), BP 7 was isolated as a white powder (67%), mp 203-205 ºC (decomp.). 
υmax (KBr) (cm-1): 3555, 3408, 3257, 3061, 2998, 2940, 2766, 2701, 1636, 1560, 1522, 1456, 
1399, 1358, 1241, 1170, 1086, 1020, 954, 918, 894, 882, 807, 767, 747, 663, 586, 525, 487, 445. 
1H NMR (300 MHz, DMSO-d6): δ 7.01 (1H, t, J 7.5, ArH, 5-H), 7.30 (1H, t, J 8.1, ArH, 6-H), 
7.45 (1H, d, J 8.4, ArH, 7-H), 8.28 (1H, d, J 8.1, ArH, 4-H). 13C NMR (75 MHz, DMSO-d6): δ 
74.6 (t, JCP 151, C(OH)(PO3H2)2), 109.6 (Ar:C-7), 119.2 (Ar:C-5), 125.2 (Ar:C-4), 125.9 (Ar:C-
6), 120.3 (Ar:C-3a), 140.9 (Ar:C-3), 142.1 (Ar:C-7a). 31P NMR (121 MHz, H3PO4/ DMSO-d6): δ 
15.4. MS (FAB) m/z: 309 ([M+H]+), 227 ([M+H]+- H3PO3). HRMS (FAB) Calcd for 
C8H11N2O7P2 309.0042 [M+H]+, found 309.0037. Found: C, 28.26, H, 4.24, N, 8.12. 
C8H10N2O7P2.2H2O requires: C, 27.92, H, 4.10, N, 8.14%.  
[1-Hydroxy-2-(1H-indazol-3-yl)ethane-1,1-diyl]bis(phosphonic acid) (9). Using the general 
procedure 2, Method B, BP 9 was isolated as a white powder (16%), mp 200-202 ºC (decomp.). 
υmax (KBr) (cm-1): 3448, 3204, 2997, 2926, 2864, 2744, 1638, 1420, 1388, 1358, 1220, 1154, 
1142, 1082, 1061, 1008, 925, 897, 843, 779, 757, 698, 536, 504, 468. 1H NMR (300 MHz, 
DMSO-d6): δ 3.57 (2H, t, JHP 13.5, NCH2C(OH)(PO3H2)2), 7.08 (1H, t, J 7.8, ArH, 5-H), 7.35 
(1H, t, J 8.1, ArH, 6-H), 7.48 (1H, d, J 8.4, ArH, 7-H), 7.77 (1H, d, J 8.1, ArH, 4-H). 13C NMR 
(75 MHz, DMSO-d6): δ 29.0 (NCH2C(OH)(PO3H2)2), 72.1 (t, JCP 143, C(OH)(PO3H2)2), 110.2 
(Ar:C-7), 120.0 (Ar:C-5), 121.1 (Ar:C-4), 126.7 (Ar:C-6), 122.6 (Ar:C-3a), 140.3 (Ar:C-7a), 
141.7 (Ar:C-3). 31P NMR (121 MHz, H3PO4/ DMSO-d6): δ 19.2. MS (ESI) m/z: 323 ([M+H]+). 
HRMS (ESI) Calcd for C9H13N2O7P2 : 323.0193 [M+H]+. Found: m/z, 323.0205. 
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